|
CN105101966A
|
|
Icotinib-containing topical skin pharmaceutical composition and use thereof
|
|
CN105377835A
|
|
Protein tyrosine kinase modulators and methods of use
|
|
CN104470929A
|
|
Crystal form of Icotinib and application thereof
|
|
CN104470526A
|
|
New polymorphic forms of icotinib phosphate and uses thereof
|
|
CN104507930A
|
|
Novel fused pyridine derivatives useful as c-Met tyrosine kinase inhibitors
|
|
TW201418254A
|
|
NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS
|
|
CN105237510A
|
|
Icotinib and icotinib hydrochloride preparation methods and intermediate
|
|
TW201339141A
|
|
A group of compounds for promoting high density lipoprotein (HDL-C) level and application thereof
|
|
TW201331192A
|
|
Amido-substituted indazole derivative as poly(ADP-ribose)polymerase inhibitors
|
|
TW201331206A
|
|
Novel fused heterocyclic derivative useful as c-Met inhibitor
|
|
WO2012062210A1
|
|
Compound for increasing kinase active and application thereof
|
|
WO2012041253A1
|
|
Compounds for increase of hdl-c level and uses thereof
|
|
WO2012006955A1
|
|
Compounds for treatment of metabolic disorders
|
|
CN103052633A
|
|
Amids Substituted Indazole Derivativees As Ploy(adp-ribose)polymerase Inhibitors
|
|
WO2012006958A1
|
|
Amids substituted indazole derivativees as ploy(adp-ribose)polymerase inhibitors
|
|
CN103052641A
|
|
Novel fused heterocyclic derivatives useful as C-Met tyrosine kinase inhibitors
|
|
WO2012003811A1
|
|
C-aryl glucoside sglt2 inhibitors and method
|
|
WO2011134284A1
|
|
Glucagon-like peptide-1 analogue and use thereof
|
|
WO2012016419A1
|
|
Glp-1 derivatives and uses thereof
|
|
CN102186881A
|
|
Glucagon-likepeptide1 derivatives and use thereof
|
